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Reply from the Authors
We thank Szczech and Winston for their interest in our
study and would like to clarify certain points. We con-
cede to the possible biases recounted; however, the intent
of our study was to evaluate the effect of angiotensin-
converting enzyme inhibition (ACEI), not antiretrovi-
ral therapy (ARV) or highly active antiretrovrial therapy
(HAART), on long-term renal survival in HIVAN. The
survival benefit of ARV, and even more so of HAART, in
human immunodeficiency virus infection is clear, but the
effects on renal survival have yet to be established. In fact,
in the referenced study by Szczech et al of more than 2000
HIV infected women, ARV monotherapy, ARV combi-
nation therapy, and HAART, all failed to affect the risk
of renal failure [1]. This was also true when those with
proteinuria were analyzed separately. In the article by
Laradi et al referenced by Szczech and Winston, history
of antiretroviral use was actually associated with worse
patient survival, making conclusions regarding the effects
of antiretrovirals on renal survival unattainable.
Higher initial CD4 counts have consistently been
shown in numerous studies, including our own, to be an
independent variable associated with better renal out-
comes. However, it does not necessarily follow that in
HIVAN decreasing the HIV viral load or increasing the
CD4 lymphocyte count will improve renal survival. This
has been suggested by case reports [3, 4], but the issue
needs to be addressed in larger prospective studies. While
we prefer not to speculate on the role of ARV or HAART
as a specific therapy for HIVAN, the authors would like
to stress the importance of early diagnosis and interven-
tion in HIVAN. There is compelling evidence that early
initiation of ACE-I improves long-term renal survival in
HIVAN.
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Home nocturnal hemodialysis
To the Editor: Home nocturnal hemodialysis (HND)
has been an established form of treatment on a world-
wide basis since its introduction in 1964 [1–4]. In its early
days, many thought that it was superior to transplantation
and was more cost effective than in center dialysis. Alas,
the passage of time has not confirmed any of these ear-
lier hopes. It is rarely practiced today for many reasons,
including the increasing age and comorbidity of the end-
stage renal population being maintained on hemodialysis,
although I still have one patient who has performed HND
4 times a week for 33 years [5]. Unless the increase in fre-
quency of HND to 5 to 7 times per week can really be
shown to be applicable on a large scale in less than highly
motivated patients and staff, I doubt that the aspirations
and claims of McFarlane et al [6] will stand the test of time
more than our hopes and aspirations of 40 years ago.
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Reply from the Authors
We agree with Dr. Shaldon that long intermittent
hemodialysis at home did not gain popularity in early
days. However, we are more optimistic than Dr. Shaldon
when considering more recent experiences [1]. The use
of quotidian nocturnal hemodialysis is increasing. In
Canada, the last few years have seen the start of at least
four new home nocturnal hemodialysis programs, and the
number of patients on the modality has doubled to more
than 150. A similar number of patients are on nocturnal
hemodialysis in the United States, and other programs
exist in The Netherlands [2], Sweden [3], Germany, and
Australia [4]. Furthermore, there are more than 300 pa-
tients primarily in the United States who are on long
1116 Letters to the Editor
intermittent hemodialysis either at home or in-center
[5].
We think that the difference in experiences between
the two eras relates to several factors. First, it has been
demonstrated that many biochemical and clinical param-
eters including quality-of-life are improved by quotidian
hemodialysis [6]. Second, as the number of programs of-
fering quotidian hemodialysis has grown, the exposure of
nephrologists and trainees to the method has increased,
resulting in a larger pool of nephrologists capable of
supervising these modalities. Third, the use of the button-
hole technique has helped resolve access difficulties in-
herent in daily hemodialysis. Fourth, industry interest has
also increased, resulting in equipment that has simplified
home hemodialysis techniques. Of course, the most im-
portant driver of growth has been patient interest, which
has risen as patients have heard of others doing well on
home-based hemodialysis.
The full potential for growth in quotidian hemodialy-
sis will not be realized until reimbursement issues have
been resolved. Although we have demonstrated that a
potential for cost savings at the global health care level,
local funding for hemodialysis consumables and capi-
tal will need to be increased [7]. We believe that when
the financial obstacles are removed and more patient-
friendly hemodialysis machines become available, quo-
tidian nocturnal and short-daily hemodialysis will be-
come the modalities of choice for an even larger number
of patients.
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Components of the IGF
system and not insulin itself
are strongly associated with
apoB100 kinetics in ESRD
To the Editor: In our accompanying paper in this is-
sue of Kidney International, insulin sensitivity tended to
be lower both in end-stage renal disease (ESRD) and in
peritoneal dialysis (PD) compared to controls. Addition-
ally, apoB100 kinetics was not associated with indexes
of insulin sensitivity. Insulin growth factors (IGFs) and
the binding proteins (IGFBPs) are key regulators of fetal
growth and development [1]. However, recently the IGF
system has been associated with metabolic pathways that
exhibit expression of a prodiabetic/proatherogenic phe-
notype [2].
Therefore, we aim to observe additional key pathways
that may be involved in the origin of dyslipidemia in pa-
tients with ESRD.
Plasma levels of IGF-1 (239 ± 12, 255 ± 44, 115 ± 12 ng/
mL), IGF-2 (658 ± 33, 765 ± 77, 470 ± 35 ng/mL),
IGFBP1 (51 ± 9, 44 ± 6, 24 ± 5 lg/L), and IGFBP3 (4.0 ±
0.2, 5.5 ± 0.5, 2.1 ± 0.2 mg/L) are all significantly higher
(P < 0.05) both in ESRD and PD compared with controls.
Significant associations were found between parameters
of the IGF system and apoB100 kinetics (Table 1). Strong
negative associations for absolute synthesis rate (ASR)
VLDL-2 apoB100, fractional catabolic rate (FCR)
VLDL-2 apoB100, transfer to IDL apoB100 and IGF-1,
IGF-2, and IGFBP3 were observed. In addition, ASR
VLDL-1 apoB100 correlated positively with IGF-1 and
IGFBP3.
These results suggest a key role for circulating IGFs
and IGFBPs involved in apoB100 kinetics. IGFBP3 ap-
peared to be involved in all found associations. Indeed,
IGFBP3 is bound in complex with either IGF-1 or IGF-2.
IGFBP3 has intrinsic properties on nuclear receptors, and
the uptake of IGFBP3 is facilitated by cholesterol in cave-
olins. Because insulin stimulates IGFBP3 synthesis [3], it
may therefore be indirectly involved in these metabolic
pathways.
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